UK’s CN Bio Innovations has licenced a Hepatitis B drug discovery programme from Bristol-Myers Squibb Company.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The programme consists of several series of small-molecule antiviral compounds identified by a Bristol-Myers Squibb screening programme before exiting virology discovery.

They act to inhibit the production of Hepatitis B surface antigen (HBsAg), which causes immune exhaustion.

CN Bio chief executive Dr Emma Sceats said: “We have already successfully used our Organ-on-Chip models to provide data and insights into drug discovery and drug safety programmes for both pharmaceutical and biotech companies.

See Also:

“The agreement is a significant opportunity as it will allow CN Bio to rapidly develop in-house anti-viral therapies and further advance our Organ-on-a-Chip discovery paradigm.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the agreement, CN Bio will discover, develop and commercialise the anti-viral compounds to create a combination treatment for chronic Hepatitis B and a monotherapy treatment for Hepatitis D infections.

Hepatitis B, the most common serious liver infection in the world, causes up to 80% of liver cancers.

"The agreement is a significant opportunity as it will allow CN Bio to rapidly develop in-house anti-viral therapies and further advance our Organ-on-a-Chip discovery paradigm."

The aggressive form of hepatitis viral infection Hepatitis D affects more than 15 million people worldwide.

CN Bio will use its liver-on-a-chip model of Hepatitis B infection ‘Quantum-B’ as a bridge to the clinic.

The platform employs human liver cells in a physiologically analogous environment and allows viral replication over several weeks.

Quantum B liver-on-a-chip models recapitulate the structure and microenvironment of the human liver sinusoid and enables the co-culture of human hepatocytes with other cell types such as Kupffer cells, NK and T-cells.

Image: A research campus operated by Bristol-Myers Squibb in Princeton, New Jersey. Photo: courtesy of Coolcaesar at the English language Wikipedia.